Actively Recruiting
Study of Maintenance Treatment Using Lurbinectedin and Serplulimab for Patients With Extensive-Stage Small Cell Lung Cancer After Initial Therapy
Led by Guangzhou Institute of Respiratory Disease · Updated on 2026-06-08
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combination of Lurbinectedin and Serplulimab as a maintenance therapy for people with extensive-stage small-cell lung cancer ES-SCLC. This Phase 2 exploratory trial follows participants who have completed initial treatment with carboplatin, etoposide, and Serplulimab and have shown an ongoing response or stable disease based on RECIST v1.1 criteria. The study aims to assess the progression-free survival after maintenance therapy begins. The study has two phases. During the induction phase, participants receive Serplulimab intravenously on Day 1, carboplatin on Day 1, and etoposide on Days 1 to 3 of each 21-day cycle, for a total of four cycles. Those who meet the criteria move to the maintenance phase, where they receive Serplulimab and Lurbinectedin intravenously on Day 1 of each 21-day cycle. Treatment continues to monitor disease status and safety. Participants will be monitored for disease progression and survival, with regular assessments up to about 24 months. Researchers will measure progression-free survival as the main outcome, along with overall survival, objective response rate, duration of response, and adverse events. Safety and response will be closely tracked during and after maintenance therapy to evaluate the combinations potential as a maintenance treatment for ES-SCLC.
CONDITIONS
Brief Title
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Research Team
M
Ming Liu, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here